Compare DBI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | SGHT |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 309.6M |
| IPO Year | 2005 | 2021 |
| Metric | DBI | SGHT |
|---|---|---|
| Price | $6.05 | $9.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.75 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 698.7K | 194.5K |
| Earning Date | 09-10-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | 15.00 | ★ 28.16 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $2,892,671,000.00 | $77,363,000.00 |
| Revenue This Year | $0.73 | $16.79 |
| Revenue Next Year | $2.01 | $11.86 |
| P/E Ratio | $18.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.11 | $3.19 |
| 52 Week High | $9.17 | $9.71 |
| Indicator | DBI | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 71.67 |
| Support Level | $5.96 | $7.70 |
| Resistance Level | $6.11 | $9.24 |
| Average True Range (ATR) | 0.31 | 0.34 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 29.89 | 74.51 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.